Evidence-graded answer
Can I still get compounded GLP-1 in 2026?
For semaglutide: no — FDA declared the shortage resolved February 21, 2025 and 503A compounding is no longer broadly permitted. For tirzepatide: shortage resolved October 2024 (re-affirmed December 2024), with a wind-down enforcement window that ended in 2025. Some clinics still market "compounded" formulations with added ingredients (B12, glycine) as personalized prescriptions; the legal status is contested.
Under FD&C Act §503A, compounding pharmacies may copy a commercial drug only when the FDA has declared a shortage. Both semaglutide and tirzepatide are off the FDA shortage list.
A few large telehealth/med-spa operators continue selling "compounded semaglutide" by adding vitamin B12 or glycine and calling it personalized — this strategy is under active FDA scrutiny and several state board actions.
For most patients, the safer (and cheaper at scale) options are now: NovoCare Pharmacy ($499/mo cash Wegovy), Lilly Direct ($349-$499/mo cash Zepbound vials), or commercial pen + manufacturer copay card.
Source: FDA: GLP-1 Compounding Updates, FDA